Building on previous research, scientists at Brown University report that a trio of proteins work together to promote a variety of lung diseases, including idiopathic pulmonary fibrosis (IPF). The findings, published by investigators led by Jack Elias in the journal Nature Communications, appeared in the article “IL-13Rα2 Uses TMEM219 In…
Researchers used stem cells from patients with idiopathic pulmonary fibrosis (IPF) to create a lung “organoid” — a three-dimensional structure similar to the human lung — that stands to improve studies into lung diseases like IPF and research into personalized drug therapies, by allowing such investigations to take place in an environment…
Researchers suggest that a certain type of the immune system cell – called myeloid-derived suppressor cells (MDSC) – can serve as a biomarker to diagnose idiopathic pulmonary fibrosis (IPF). These cells may also distinguish stages of disease progression, as a greater loss of lung function was found in patients with higher levels of MDSCs in…
Long-term treatment of idiopathic pulmonary fibrosis (IPF) patients with Ofev (nintedanib) showed positive effects in keeping disease progression at bay, while inducing manageable side effects, Boehringer Ingelheim Pharmaceuticals announced. This finding comes from the INPULSIS-ON clinical trial — an extension study of the INPULSIS trial — designed to assess the long-term effects of…
A new study suggests that metformin, a drug widely used to treat diabetes, can benefit people with idiopathic pulmonary fibrosis (IPF) by working to diminish lung fibrosis. The study, “Metformin Attenuates Lung Fibrosis Development Via NOX4 Suppression,” was published in the journal Respiratory Research by Nahoko Sato, MD, and…
Get regular updates to your inbox.
